Scripps Research scientists explain what makes COVID-19 antibody “J08” so potent

LA JOLLA, CA — Last year, scientists at Scripps Research and Toscana Life Sciences studied the blood of 14 COVID-19 survivors to find the most potent antibodies against the SARS-CoV-2 virus. One of the leading molecules that emerged — now in stage II / III trials in Italy — was an antibody dubbed J08, which seemed to be capable of both preventing and treating COVID-19.

Now, the same group — a collaboration between scientists at Scripps Research and in Italy and France — has visualized exactly how J08 binds to different SARS-CoV-2 variants in different conformations, explaining what makes the monoclonal antibody so potent. The research, published in Proceedings of the National Academy of Sciences, suggests that the J08 antibody, because of its flexibility, will likely remain effective against future variants of COVID-19.

“Even though we can’t predict what variants of COVID-19 will emerge next, understanding the details of J08 reveals what works against the virus, and perhaps how we can engineer antibodies to be even more potent,” says senior author Andrew Ward, PhDprofessor of Integrative Structural and Computational Biology at Scripps Research.

When a person is exposed to a virus like SARS-CoV-2, their body generates a variety of antibodies that bind to different sections of the virus to clear it from the body. Scientists designing vaccines and treatments against COVID-19 are interested in what makes some of these naturally produced antibodies — like J08 — more effective than others. In the months after Ward and his collaborators first identified J08, it became clear that the antibody, unlike many others, was potent against a variety of COVID-19 variants.

In the new work, the researchers determined the three-dimensional structure of J08 as it bound to the spike protein of SARS-CoV-2. They confirmed that J08 successfully attached to the Alpha, Beta, Gamma and Delta variants and neutralized the viruses — preventing them from replicating. However, J08 attached to the Omicron variant about 7 times more slowly, and then rapidly came off. About 4,000 times more J08 was needed to fully neutralize Omicron SARS-CoV-2 compared to the other variants.

“With variants other than Omicron, this antibody binds quickly and doesn’t come off for hours and hours,” says co-first author Gabriel Ozorowski, a senior staff scientist in the Ward lab at Scripps Research. “With Omicron, we were initially happy to find that it still binds, but it falls off very quickly. We identified the two structural changes that cause this. ”

The team showed that, for all the variants, J08 binds to a very small section of the virus — a section that generally stays the same even as the virus mutates. Moreover, J08 could attach in two completely different orientations, like a key that manages to unlock a door whether it is right side up or upside down.

“This small, flexible footprint is part of why J08 is able to withstand so many mutations — they don’t impact the antibody binding unless they happen to be in this one very small part of the virus,” says co-first author Jonathan Torres , lab manager of the Ward lab at Scripps Research.

The Omicron variant of SARS-CoV-2, however, had two mutations (known as E484A and Q493H) that changed the small area of ​​the virus that directly interfaces with J08, anchoring it in place. Ward and his collaborators found that if just one of these mutations is present, J08 still manages to bind and neutralize the virus strongly, but mutations in both are what make it less effective against the Omicron variant.

The researchers say the new results support the continued clinical trials of the monoclonal antibody based on J08.

“I think we’re pretty confident that future variants won’t necessarily have both of these two critical mutations at the same time like Omicron,” says Ozorowski, “so that makes us hopeful that J08 will continue to be very effective.”

In addition to Torres, Ozorowski and Ward, authors of the study, “Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody, ”Include Hejun Liu, Jeffrey Copps and Ian Wilson of Scripps Research; Emanuele Andreano, Noemi Manganaro, Elisa Pantano, Ida Paciello, Piero Pileri, Claudia Sala and Rino Rappuoli of Fondazione Toscana Life Sciences; Giulia Piccini and Emanuele Montomoli of VisMederi; Lorena Donnici, Matteo Conti and Raffaele De Francesco of Istituto Nazionale Genetica Molecolare (INGM); and Cyril Planchais, Delphine Planas, Timothee Bruel, Hugo Mouquet and Olivier Schwartz of Institut Pasteur.

This work was supported by funding from Toscana Life Sciences, through the European Research Council (ERC) advanced grant agreement number 787552 (vAMRes), the European Union’s Horizon 2020 research and innovation program (653316), the Italian Ministry of Health (COVID-2020 -12371817), Pasteur Institute, COVID-19 Fundraising Campaign of Pasteur Institute, ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR / FRM Flash Covid PROTEO-SARS-CoV-2, IDISCOVR, and the Bill & Melinda Gates Foundation (OPP1170236 / INV-004923).

About Scripps Research

Scripps Research is an independent, nonprofit biomedical institute ranked the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at www.scripps.edu.

/ Public Release. This material from the originating organization / author (s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author (s) .View in full here.

Leave a Reply

Your email address will not be published.